moneyheap
DAWN · Analysis updated Mar 9, 2026, 4:30 PM ET
Why is Day One Biopharmaceuticals, Inc. Common Stock (DAWN) stock moving?
Day One Biopharmaceuticals (DAWN) experienced a massive 65.88% price surge on March 6, 2026, closing at $21.20 after announcing a definitive agreement to be acquired by Servier for $21.50 per share in cash. This transaction, valued at $2.5 billion, effectively caps the stock's upside as it now trades just pennies below the buyout price. Market data reflects this paradigm shift, with volume exploding to 145,291 units on the news day—nearly 30 times the average—as traders priced in the acquisition premium. While fundamental milestones like the positive CHMP opinion for OJEMDA in Europe and strong 2025 revenue ($155.4M) support the valuation, multiple analysts (Needham, Wedbush, Jones Trading) have downgraded the stock to 'Hold' or 'Neutral,' reflecting that the 'deal premium' is now fully baked into the price. Short-term volatility may persist due to minor arbitrage or potential legal investigations into the deal's fairness, but the stock is expected to remain anchored near $21.50 until the acquisition closes in Q2 2026.
News behind the analysis
- Day One Biopharmaceuticals to Merge with Servier for $2.5 BillionDay One Biopharmaceuticals has entered a definitive agreement to be acquired by Servier for $21.50 per share in cash, a 68% premium over the March 5 closing price.
- DAWN Stock Jumps 66% on $2.5B Buyout Offer From ServierShares of DAWN skyrocketed following the announcement of its acquisition, which will add the FDA-approved drug OJEMDA to Servier's rare oncology portfolio.
- Day One Biopharmaceutical (DAWN) Downgraded by NeedhamFollowing the acquisition news, Needham downgraded DAWN from Buy to Hold as the share price reached the cash offer level.
- Wedbush Reaffirms Neutral Rating, Cuts Price Target to $21.50Wedbush adjusted its price target for DAWN to match the Servier acquisition price, suggesting limited further upside.
- Halper Sadeh LLC Investigates Sale of Day One BiopharmaceuticalsAn investor rights law firm is investigating whether the $21.50 per share sale to Servier is fair to DAWN shareholders.
- tickernerd.comSource identified via Google Search grounding.
- stockinvest.usSource identified via Google Search grounding.
- stocktwits.comSource identified via Google Search grounding.
- finviz.comSource identified via Google Search grounding.
- bioworld.comSource identified via Google Search grounding.
- directorstalkinterviews.comSource identified via Google Search grounding.